High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6‐RUNX1‐positive acute lymphoblastic leukemia
Pediatric Blood & Cancer2019Vol. 66(8), pp. e27780–e27780
Citations Over TimeTop 17% of 2019 papers
Jana Hoffmann, Manuela Krumbholz, Helia Pimentel Gutiérrez, Marion Fillies, Annabell Szymansky, Kirsten Bleckmann, Udo zur Stadt, Rolf Köhler, Roland P. Kuiper, Martin A. Horstmann, Arend von Stackelberg, Cornelia Eckert, Markus Metzler
Abstract
ETV6-RUNX1 fusion sites are highly sensitive and reliable MRD markers. Our data confirm that they are unaffected by clonal evolution and selection during front-line and second-line chemotherapy in contrast to Ig/TCR rearrangements, which require several markers per patient to compensate for the observed loss of target clones. In future studies, the genomic ETV6-RUNX1 fusion can be used as single MRD marker.
Related Papers
- → Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes(1994)137 cited
- → Gene rearrangement study for minimal residual disease monitoring in children with acute lymphocytic leukemia(2013)8 cited
- → The use of monoclonal gene rearrangement for detection of minimal residual disease in acute lymphoblastic leukemia of childhood(1997)25 cited
- → Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes(1994)8 cited
- → Minimal Residual Disease Monitoring in Childhood Precursor B Lymphoblastic Leukemia with t(12;21)(p13;q22); ETV6-RUNX1: A Comparison Between Quantitative RT-PCR and Flow Cytometry(2014)